Nucleics moved on the 26th May 2003 to the Biotechnology precinct of the Australian Technology Park, Redfern, Australia. This move allows Nucleics to significantly expand our R&D base and provides a platform for future growth of our software … [Read more]
General manager appointed
Nucleics has appointed Mr David Gemmola to the newly created position of General Manager. David has extensive experience in the management and growth of early stage high technology companies. He brings to Nucleics a focus on product development and … [Read more]
CounterTrace DNA Sequencing Kit Released
Nucleics announces the public launch of the CounterTrace DNA sequencing kit. CounterTrace combines a propriety DNA standard and trace reprocessing software that provides increases in DNA trace read lengths of up to 65% with average increases of 25%. … [Read more]
Nucleics launches the UniSeq genome DNA sequencing kit
Nucleics announces the launched of the UniSeq™ genome DNA sequencing kit. This innovative technology allows the user to rapidly and efficiently sequence any DNA region and is based on the UniPrime™ technology developed by Nucleics. UniPrime utilizes … [Read more]
Protein expression & purification subsidiary established
Nucleics announces the establishment of Protigene, a fully-owned subsidiary of Nucleics. Protigene is focused on the commercialization of novel protein expression and purification technologies developed by Nucleics scientists. Protigene's CEO, Dr … [Read more]
Nucleics scientists develop novel protein purification system
Z-Tag is a novel and versatile protein purification technology developed by Nucleics that provides a number of superior properties over currently available protein purification systems. The Z-Tag™ system employs a novel protein fusion technology to … [Read more]
Nucleics to sequence the Streptococcus gordonii genome
Nucleics announces a project to sequence the Streptococcus gordonii DL1 genome using the ASIN genome sequencing technology developed by Nucleics. Streptococcus gordonii is an oral pathogen that can cause severe heart valve damage. This project is … [Read more]
Nucleics awarded an R&D START grant to develop new DNA sequencing technologies
Nucleics has been awarded a three year R&D START grant of $1,834,000 from AusIndustry to develop new automated DNA sequencing technologies. These integrated technologies improve the preparation of the DNA template, the selection of the required … [Read more]
Nucleics sells the ASIN genome sequencing technology to Takara Biomedicals
Nucleics announces the sale of its novel genome DNA sequencing technology (ASIN) to Takara Biomedicals, a division of Takara Shuzo. Under the terms of the agreement, Takara has purchased all IP associated with the ASIN sequencing technology. Takara … [Read more]
- « Previous Page
- 1
- …
- 21
- 22
- 23